CELC Celcuity Inc.
Price Chart
Executive Summary
Celcuity announced a proposed $400M underwritten public offering of convertible senior notes due 2032. The offering is dilutive to existing shareholders and signals significant capital needs for a clinical-stage biotech, likely to fund pipeline development. Given the company's pre-revenue status and the large size relative to its $4.5B market cap, this is a notable but not transformative event.
Key Financial Metrics
Actionable Insight
Traders should monitor the pricing and conversion terms of the notes. The offering could pressure the stock in the near term due to dilution concerns, but if proceeds are used for a transformative catalyst (e.g., late-stage trial results), the long-term outlook may improve. Watch for the final prospectus and any updates on use of proceeds.
Key Facts
- Proposed underwritten public offering of $400M aggregate principal amount of convertible senior notes due 2032.
- Celcuity is a clinical-stage biotechnology company with no approved products or disclosed revenue.
- The offering represents approximately 8.9% of the company's $4.5B market cap.
- Convertible notes will likely convert into equity, adding dilution over time.
Financial Impact
$400M convertible note offering, representing ~8.9% of market cap
Risk Factors
- Dilution from conversion of notes could exceed 8.9% if stock price appreciates.
- Clinical-stage biotech risk: no revenue, pipeline failure could render debt burdensome.
- Market may view large offering as a sign of cash burn or desperation, especially given historical poor performance of prior bullish calls on CELC.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305935 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $89.78 awaiting T+1 | awaiting T+1 | — | $88.55 (−1.37%) |
|
Jun 8, 2026
4d ago
|
8-K
| $87.39 awaiting T+1 | awaiting T+1 | — | $88.55 (+1.33%) |
|
Jun 5, 2026
8d ago
|
424B5
| $92.47 awaiting T+1 | awaiting T+1 | — | $88.55 (−4.24%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $92.47 $88.28 | ▼ −4.53% | ▼ −1.93% | $88.55 (−4.24%) |
|
Jun 3, 2026
9d ago
|
Press Release
| $88.95 $92.47 | ▼ −3.96% | ▼ −3.56% | $88.55 (+0.45%) |
|
Jun 3, 2026
9d ago
|
424B5
| $88.95 $92.47 | ▼ −3.96% | ▼ −3.56% | $88.55 (+0.45%) |
|
Jun 2, 2026
10d ago
|
8-K
| $91.42 $88.95 | ▼ −2.70% | ▼ −2.01% | $88.55 (−3.14%) |
|
May 14, 2026
29d ago
|
Press Release
| $137.68 $132.18 | ▼ −3.99% | ▼ −3.93% | $88.55 (−35.68%) |
|
May 7, 2026
5w ago
|
Press Release
| $130.71 $131.06 | ▲ +0.27% | ▼ −0.56% | $88.55 (−32.25%) |
|
May 4, 2026
5w ago
|
144
| $144.98 $141.69 | ▼ −2.27% | ▼ −3.06% | $88.55 (−38.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access